About Taligen Therapeutics
Taligen Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2004, and was acquired by Alexion in January 2011. Protein therapeutics for inflammatory diseases. Taligen Therapeutics has raised $101.05 million across 3 funding rounds from investors including Blackstone, Alexion and Sanderling Ventures. Its focus areas include Life Sciences, Immunology, Drugs and Inflammatory Diseases. Its legal entity is TALIGEN THERAPEUTICS, INC. Its competitors include Aclaris Therapeutics, Escient Pharmaceuticals and MacroGenics; 3 of its 3 listed competitors have raised funding.
Company details
Taligen Therapeutics was founded in 2004 in Cambridge, United States, within the biotechnology sector. Protein therapeutics targeting the alternative complement pathway were developed to address inflammatory conditions. Monoclonal antibodies and recombinant fusion proteins were created as lead candidates for various diseases. Operations focused on modulating immune responses. The company was acquired by Alexion Pharmaceuticals for 111 million.
- Headquarters Cambridge, United States
- Stage Acquired
- SectorsHealthcare
- Website taligentherapeutics.com
- Social LinkedIn
- Acquired by Alexion (Jan 2011)
- Legal Name Taligen Therapeutics, Inc
- Total Equity Funding$101.05M (USD)
in 3 rounds
- Latest Funding Round$36.05M (USD), Series B
Aug 2010
- InvestorsBlackstone
& 4 more
- Acquired byAlexion
(Jan 2011)
Funding Insights of Taligen Therapeutics
Taligen Therapeutics has successfully raised a total of $101.05M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $36.05 million completed in August 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $101.05M
- Total Rounds 3
- Last Round Series B — $36.05M
- Investors Count 4
All 3 funding rounds of Taligen Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2010 | $36.05M | Series B | – | – | – |
| Jan 2008 | $65M | Series B | – | Alta Partners, Blackstone | |
| Aug 2005 | Series A | – | – |
5 investors in total: 5 institutional.
Investors in Taligen Therapeutics
Taligen Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Blackstone, Alexion and Sanderling Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biomedical investment financing and active management services. | sanderling.com | |||
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Early-stage centric life sciences and tech focused VC firm investing primarily in the US | highcountryventure.com | Boulder, United States | ||
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
Therapies for rare and devastating diseases are developed by Alexion. | 1992 | alexion.com | Zurich, Switzerland |
Investor details for Taligen Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Taligen Therapeutics
4 dated milestones of Taligen Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Taligen Therapeutics is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $36.0M.
- Exit Acquired by Alexion.
Competitors of Taligen Therapeutics
Taligen Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Aclaris Therapeutics, Escient Pharmaceuticals and MacroGenics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| macrogenics.com | 2000 | Rockville, United States | $126.02M | 339 | A biopharmaceutical company focused on cancer therapeutics development. |
Detailed competitors of Taligen Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Taligen Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Taligen Therapeutics
Taligen Therapeutics was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Taligen Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Taligen Therapeutics is a funded company, having raised a total of $101.05M across 3 funding rounds to date.
Taligen Therapeutics was founded in 2004 in Cambridge, United States, within the biotechnology sector. Protein therapeutics targeting the alternative complement pathway were developed to address inflammatory conditions. Monoclonal antibodies and recombinant fusion proteins were created as lead candidates for various diseases. Operations focused on modulating immune responses. The company was acquired by Alexion Pharmaceuticals for 111 million.
Taligen Therapeutics's top competitors include Escient Pharmaceuticals, MacroGenics and Aclaris Therapeutics.
Taligen Therapeutics has 5 investors. Key investors include Blackstone, Alexion, Sanderling Ventures, Alta Partners, and High Country Ventures.
Taligen Therapeutics operates through Taligen Therapeutics, Inc.
Yes. Taligen Therapeutics was acquired by Alexion in January 2011.